KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Current Leases (2020 - 2025)

Travere Therapeutics (TVTX) has disclosed Current Leases for 6 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 8.7% year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Dec 2025, up 8.7%, and an annual FY2025 reading of $5.9 million, up 8.7% over the prior year.
  • Current Leases was $5.9 million for Q4 2025 at Travere Therapeutics, up from $5.7 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.9 million in Q4 2025 and bottomed at $3.9 million in Q4 2021.
  • Average Current Leases over 5 years is $4.9 million, with a median of $4.9 million recorded in 2023.
  • The sharpest move saw Current Leases soared 994.68% in 2021, then rose 8.25% in 2025.
  • Year by year, Current Leases stood at $3.9 million in 2021, then increased by 13.43% to $4.4 million in 2022, then increased by 10.74% to $4.9 million in 2023, then rose by 10.1% to $5.4 million in 2024, then rose by 8.7% to $5.9 million in 2025.
  • Business Quant data shows Current Leases for TVTX at $5.9 million in Q4 2025, $5.7 million in Q3 2025, and $5.6 million in Q2 2025.